



Vaccines for Ebola Virus and Related Diseases

Guest Editor:

Prof. Dr. David A. Schwartz

Medical College of Georgia,
Augusta University, Augusta, GA
30912, USA

Deadline for manuscript
submissions:

closed (31 December 2020)

Message from the Guest Editor

Dear Colleagues,

I am pleased to invite you to prepare a contribution to our upcoming special issue on vaccines for Ebola virus disease (EVD) and related diseases. EVD is an important disease in sub-Saharan Africa, reaching its historic clinical impact during 2013–2016 West Africa epidemic.

This topical issue of *Vaccines* welcomes contributions dealing with all aspects of the design, development, testing and administration of current and future vaccines for Ebola virus and related viruses including Marburg virus. We also welcome contributions dealing with Ebola vaccine policy and social issues relating to accessibility of vaccines, Ebola vaccine use during humanitarian crises, epidemiological methods for assessing Ebola vaccine efficacy and safety, preventive and reactive uses of the vaccine, vaccine distribution, vaccination of special groups including pregnant women, infants and children and persons with simultaneous co-infections, vaccines and sexual transmission, Ebola vaccine hesitancy, and other important topics relating to these life-saving vaccines.

Prof. David A. Schwartz
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com